Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
UNICHEM LAB ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
UNICHEM LAB Mar-23 |
ADCOCK INGRAM Jun-14 |
UNICHEM LAB/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 467 | 316 | - | |
Low | Rs | 226 | 228 | - | |
Sales per share (Unadj.) | Rs | 190.7 | 94.0 | - | |
Earnings per share (Unadj.) | Rs | -28.7 | -23.7 | - | |
Cash flow per share (Unadj.) | Rs | -12.6 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 344.2 | 73.8 | - | |
Shares outstanding (eoy) | m | 70.41 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.8 | 2.9 | 62.8% | |
Avg P/E ratio | x | -12.1 | -11.5 | 105.1% | |
P/CF ratio (eoy) | x | -27.5 | -13.9 | 198.3% | |
Price / Book Value ratio | x | 1.0 | 3.7 | 27.3% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 24,396 | 45,919 | 53.1% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 3,564 | 2,882 | 123.7% | |
Avg. sales/employee | Rs Th | 0 | 3,696.8 | - | |
Avg. wages/employee | Rs Th | 0 | 671.3 | - | |
Avg. net profit/employee | Rs Th | 0 | -931.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 13,430 | 15,870 | 84.6% | |
Other income | Rs m | 385 | 111 | 346.6% | |
Total revenues | Rs m | 13,815 | 15,982 | 86.4% | |
Gross profit | Rs m | -841 | -2,750 | 30.6% | |
Depreciation | Rs m | 1,134 | 685 | 165.6% | |
Interest | Rs m | 173 | 430 | 40.3% | |
Profit before tax | Rs m | -1,764 | -3,754 | 47.0% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 259 | 235 | 110.3% | |
Profit after tax | Rs m | -2,022 | -3,999 | 50.6% | |
Gross profit margin | % | -6.3 | -17.3 | 36.1% | |
Effective tax rate | % | -14.7 | -6.2 | 234.7% | |
Net profit margin | % | -15.1 | -25.2 | 59.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 15,885 | 11,624 | 136.7% | |
Current liabilities | Rs m | 6,396 | 6,540 | 97.8% | |
Net working cap to sales | % | 70.7 | 32.0 | 220.6% | |
Current ratio | x | 2.5 | 1.8 | 139.7% | |
Inventory Days | Days | 51 | 111 | 46.2% | |
Debtors Days | Days | 1,600 | 124 | 1,290.7% | |
Net fixed assets | Rs m | 15,911 | 6,775 | 234.8% | |
Share capital | Rs m | 141 | 74 | 191.1% | |
Net worth | Rs m | 24,233 | 12,457 | 194.5% | |
Long term debt | Rs m | 636 | 4,377 | 14.5% | |
Total assets | Rs m | 31,829 | 23,531 | 135.3% | |
Interest coverage | x | -9.2 | -7.7 | 118.8% | |
Debt to equity ratio | x | 0 | 0.4 | 7.5% | |
Sales to assets ratio | x | 0.4 | 0.7 | 62.6% | |
Return on assets | % | -5.8 | -15.2 | 38.3% | |
Return on equity | % | -8.3 | -32.1 | 26.0% | |
Return on capital | % | -6.4 | -19.8 | 32.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -851 | 1,355 | -62.8% | |
From Investments | Rs m | 2,028 | -416 | -487.6% | |
From Financial Activity | Rs m | -813 | 3,973 | -20.5% | |
Net Cashflow | Rs m | 746 | 4,912 | 15.2% |
Compare UNICHEM LAB With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare UNICHEM LAB With: SYNCOM HEALTHCARE MAKERS LAB. HESTER BIOSCIENCES PANCHSHEEL ORG MARKSANS PHARMA.
Asian markets traded higher on Tuesday following overnight gain on Wall Street.